个人科研网厅 | | 帮助
高级检索
当前位置： 首页 > 详情页

Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Zhao, Hong[1,2] * ; Zhou, Aiping[3] ; Zhou, Jianguo[1] ; Bi, Xinyu[1,2] ; Yan, Shida[1] ; Jin, Jing[4] ; Wei, Wenqiang[5] ; Li, Muxing[6] ; Gong, Caifeng[3] ; Chen, Qichen[1] ; Luo, Zhiwen[1] ; Li, Ning[4] ; Mao, Rui[1] ; Chen, Xiao[1] ; Chen, Bo[4] ; Zheng, Rongshou[5] ; Zhao, Jianjun[1] ; Han, Yue[7] ; Li, Zhiyu[1] ; Che, Xu[8,9,10] ; Tang, Yuan[4] ; Sun, Yongkun[3] ; Huang, Zhen[1] ; Zhang, Yefan[1] ; Wang, Xiaoying[11,12] ; Zhang, Yubao[13] ; Lu, Zhenhui[14] ; Dang, Xiaowei[15] ; Song, Tianqiang[16] ; Liu, Chang[17] ; Yue, Ping[18] ; Yan, Dong[19] ; Yue, Aimin[20] ; Zhang, Rui[21] ; Luo, Suxia[22] ; Tan, Jing[23] ; Zhang, Xuewen[24] ; Bai, Xuel[25] ; Zhang, Xuejun[26] ; He, Mingyan[27] ; Xie, Yujun[28] ; Wang, Wenling[29] ; Yang, Po[30] ; Yang, Yijun[31] ; Zhang, Yamin[32] ; Li, Qingdong[33] ; Peng, Tao[34] ; Wang, Zusen[35] ; Chen, Yajin[36] ; Shang, Changzhen[36] ; Liang, Yingjian[37] ; Zhang, Bixiang[38] ; Zhang, Feng[39] ; Wang, Liming[40] ; Li, Duo[41] ; Liu, Bin[42] ; Zhu, Xiaofeng[43] ; Hu, Qinggang[44] ; Chen, Minshan[45] ; Xiu, Dianrong[6] ; Xia, Feng[46] ; Zhang, Yanqiao[47] ; Zeng, Yong[48] ; Mao, Yilei[49] ; Li, Xun[18] ; Ba, Yi[50] ; Liang, Tingbo[25] ; Shen, Feng[51] ; Liu, Lianxin[52] ; Cai, Xiujun[53] ; Zhou, Jian[11,12] ; Cai, Jianqiang[1,2,*1] ;
单位： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Hepatobiliary Surg, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Gene Editing Screening & R&D Digest Syst, Beijing, Peoples R China [3]Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Beijing, Peoples R China [4]Chinese Acad Med Sci & Peking Union Med Coll, Dept Radiat Oncol, Beijing, Peoples R China [5]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Off Canc Registry, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [6]Peking Univ Third Hosp, Dept Gen Surg, Beijing, Peoples R China [7]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Intervent Therapy, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [8]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Pancreat & Gastr Surg, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [9]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Hepatobiliary & Pancreat Surg, Natl Canc Ctr,Canc Hosp, Shenzhen, Peoples R China [10]Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China [11]Fudan Univ, Zhongshan Hosp, Dept Liver Surg, Shanghai, Peoples R China [12]Fudan Univ, Zhongshan Hosp, Liver Transplant Ctr, Shanghai, Peoples R China [13]Harbin Med Univ, Canc Hosp, Dept Hepatobiliary & Pancreat Surg, Harbin, Peoples R China [14]Ningxia Med Univ, Gen Hosp, Dept Hepatobiliary Surg, Yinchuan, Ningxia, Peoples R China [15]Zhengzhou Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Zhengzhou, Peoples R China [16]Tianjin Med Univ Canc Inst & Hosp, Dept Hepatobiliary Canc, Tianjin, Peoples R China [17]Xi An Jiao Tong Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Xian, Peoples R China [18]Lanzhou Univ, Hosp 1, Dept Gen Surg, Lanzhou, Peoples R China [19]Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Hepatopancreatobiliary Surg, Urumqi, Peoples R China [20]Xinxiang Cent Hosp, Dept Surg Oncol, Xinxiang, Henan, Peoples R China [21]China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Colorectal Surg, Shenyang, Peoples R China [22]Henan Canc Hosp, Zhengzhou, Peoples R China [23]Kunming Med Univ, Yanan Affiliated Hosp, Kunming, Yunnan, Peoples R China [24]Jilin Univ, Hosp 2, Dept Hepatobiliary & Pancreat Surg, Changchun, Peoples R China [25]Zhejiang Univ, Zhejiang Clin Res Cneter Hepatobiliary & Pancreat, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp 1,Sch Med, Hangzhou, Peoples R China [26]Inner Mongolia Peoples Hosp, Dept Intervent, Hohhot, Peoples R China [27]Gansu Prov Canc Hosp, Dept Abdominal Surg 3, Lanzhou, Peoples R China [28]Ningxia Peoples Hosp, Dept Intervent Ultrasound, Yinchuan, Ningxia, Peoples R China [29]Guizhou Med Univ, Affiliated Canc Hosp, Dept Oncol, Guiyang, Peoples R China [30]Harbin Med Univ, Hosp 4, Dept Intervent & Vasc Therapy, Harbin, Peoples R China [31]Haikou Municipal Hosp, Dept Hepatobiliary Surg, Haikou, Hainan, Peoples R China [32]Tianjin First Ctr Hosp, Dept Hepatobiliary Surg, Tianjin, Peoples R China [33]Chongqing Univ, Canc Hosp, Vasc & Intervent Dept, Chongqing, Peoples R China [34]Guangxi Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Nanning, Peoples R China [35]Qingdao Univ, Dept Hepatobiliary Surg, Affiliated Hosp, Qingdao, Peoples R China [36]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Dept Hepatobiliary Surg, Guangzhou, Peoples R China [37]Harbin Med Univ, Dept Gen Surg, Affiliated Hosp 1, Harbin, Peoples R China [38]Huazhong Univ Sci & Technol, Tongji Med Coll, Tongji Hosp, Hepat Surg Ctr, Wuhan, Peoples R China [39]Hubei Canc Hosp, Dept Hepatobiliary & Pancreat Surg, Wuhan, Peoples R China [40]Dalian Med Univ, Dept Hepatobiliary & Pancreat Surg, Hosp 2, Dalian, Peoples R China [41]Hainan Canc Hosp, Dept Hepatopancreatobiliary Surg, Haikou, Hainan, Peoples R China [42]Kunming Med Univ, Affiliated Hosp 1, Dept Hepatobiliary & Pancreat Surg, Kunming, Peoples R China [43]Sun Yat Sen Univ, Dept Transplantat, Affiliated Hosp 1, Guangzhou, Peoples R China [44]Huazhong Univ Sci & Technol, Tongji Med Coll, Dept Hepatobiliary Surg, Union Hosp, Wuhan, Peoples R China [45]Sun Yat Sen Univ, Ctr Canc, Dept Hepatobiliary Surg, Guangzhou, Peoples R China [46]Army Med Univ, Southwest Hosp, Inst Hepatobiliary Surg, Chongqing, Peoples R China [47]Harbin Med Univ, Canc Hosp, Dept Gastrointestinal Med Oncol, Harbin, Peoples R China [48]Sichuan Univ, West China Hosp, Dept Liver Surg, Chengdu, Peoples R China [49]Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Liver Surg, Beijing, Peoples R China [50]Tianjin Med Univ, Natl Clin Res Ctr Canc, Tianjins Clin Res Ctr Canc, Key Lab Canc Prevent & Therapy,Canc Inst & Hosp, Tianjin, Peoples R China [51]Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepatobiliary Surg, Shanghai, Peoples R China [52]Univ Sci & Technol China, Affiliated Hosp 1, Dept Hepatobiliary Surg, Hangzhou, Peoples R China [53]Zhejiang Univ, Sir Run Shaw Hosp, Sch Med, Hangzhou, Peoples R China
出处：
DOI： 10.1016/j.hpb.2021.07.002
ISSN：

摘要：
Background: This study aimed to investigate the work status of clinicians in China and their management strategy alteration for patients with hepatocellular carcinoma (HCC) during the COVID-19 pandemic. Methods: A nationwide online questionnaire survey was conducted in 42 class-A tertiary hospitals across China. Experienced clinicians of HCC-related specialties responded with their work status and management suggestions for HCC patients during the pandemic. Results: 716 doctors responded effectively with a response rate of 60.1%, and 664 were included in the final analysis. Overall, 51.4% (341/664) of clinicians reported more than a 60% reduction of the regular workload and surgeons declared the highest proportion of workload reduction. 92.5% (614/664) of the respondents have been using online medical consultation to substitute for the "face-to-face" visits. Adaptive adjustment for the treatment strategy for HCC was made, including the recommendations of noninvasive and minimally invasive treatments such as transcatheter arterial chemoembolization for early and intermediate stage. Targeted therapy has been the mainstay for advanced stage and also as a bridge therapy for resectable HCC. Discussion: During the COVID-19 pandemic, online medical consultation is recommended to avoid social contact. Targeted therapy as a bridge therapy is recommended for resectable HCC considering the possibility of delayed surgery.

基金：
State Key Project on Infection Diseases of China [2017ZX10201021-007-003]; CAMS Innovation Fund for Medical Sciences (CIFMS) [2017-12M-4-002]; Key Laboratory Project of Chinese Academy of Medical Sciences [2019PT310026]
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2021]版：
大类 | 3 区 医学
小类 | 3 区 胃肠肝病学 3 区 外科
最新[2025]版：
大类 | 3 区 医学
小类 | 3 区 胃肠肝病学 3 区 外科
JCR分区：
出版当年[2020]版：
Q1 SURGERY Q3 GASTROENTEROLOGY & HEPATOLOGY
最新[2023]版：
Q1 SURGERY Q2 GASTROENTEROLOGY & HEPATOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2020版] 出版当年五年平均 出版前一年[2019版] 出版后一年[2021版]

第一作者：
第一作者单位： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Hepatobiliary Surg, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Gene Editing Screening & R&D Digest Syst, Beijing, Peoples R China
通讯作者：
通讯机构： [1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Dept Hepatobiliary Surg, Natl Canc Ctr,Canc Hosp, Beijing, Peoples R China [2]Chinese Acad Med Sci & Peking Union Med Coll, Key Lab Gene Editing Screening & R&D Digest Syst, Beijing, Peoples R China [*1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Canc Hosp, 17 Panjiayuannanli, Beijing 100021, Peoples R China
推荐引用方式(GB/T 7714)：
Zhao Hong,Zhou Aiping,Zhou Jianguo,et al.Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey[J].HPB.2022,24(3):342-352.doi:10.1016/j.hpb.2021.07.002.
APA：
Zhao, Hong,Zhou, Aiping,Zhou, Jianguo,Bi, Xinyu,Yan, Shida...&Cai, Jianqiang.(2022).Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey.HPB,24,(3)
MLA：
Zhao, Hong,et al."Chinese expert recommendations on management of hepatocellular carcinoma during COVID-19 pandemic: a nationwide multicenter survey".HPB 24..3(2022):342-352

资源点击量：426 今日访问量：2 总访问量：410 更新日期：2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有：重庆聚合科技有限公司 渝ICP备12007440号-3 地址：重庆市两江新区泰山大道西段8号坤恩国际商务中心16层（401121）